|
|
Volumn 101, Issue 14, 2009, Pages 980-982
|
|
JAK2 inhibitors: Not the next imatinib but researchers see other possibilities
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AZD 1480;
CYT 387;
IMATINIB;
INCB 018424;
JANUS KINASE 2;
JANUS KINASE INHIBITOR;
JANUS TYROSINE KINASE 2 INHIBITOR;
LESTAURTINIB;
PHENYLALANINE;
TG 101348;
UNCLASSIFIED DRUG;
VALINE;
XL 019;
ACUTE LYMPHOBLASTIC LEUKEMIA;
ADVANCED CANCER;
AMINO ACID SUBSTITUTION;
BONE MARROW CELL;
CANCER SURVIVAL;
CELL DIFFERENTIATION;
CELL PROLIFERATION;
CHRONIC MYELOID LEUKEMIA;
CLINICAL RESEARCH;
CLINICAL TRIAL;
DISEASE COURSE;
DISEASE SEVERITY;
DRUG EFFICACY;
DRUG SAFETY;
ERYTHROCYTE;
FATIGUE;
FOOD AND DRUG ADMINISTRATION;
GENE MUTATION;
HEMORRHAGIC STROKE;
HUMAN;
INCIDENCE;
MOLECULAR GENETICS;
MYELOFIBROSIS;
MYELOPROLIFERATIVE DISORDER;
NIGHT SWEAT;
NOTE;
POLYCYTHEMIA VERA;
PRIORITY JOURNAL;
PRURITUS;
QUALITY OF LIFE;
SIGNAL TRANSDUCTION;
SPLENOMEGALY;
STROKE;
THROMBOCYTHEMIA;
TREATMENT RESPONSE;
ANIMALS;
ANTINEOPLASTIC AGENTS;
HUMANS;
JANUS KINASE 2;
LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;
MYELOPROLIFERATIVE DISORDERS;
PIPERAZINES;
POINT MUTATION;
POLYCYTHEMIA VERA;
PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;
PRIMARY MYELOFIBROSIS;
PROTEIN KINASE INHIBITORS;
PYRIMIDINES;
SIGNAL TRANSDUCTION;
THROMBOCYTOSIS;
|
|
EID: 67650828139
PISSN: 00278874
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djp216 Document Type: Note |
|
Times cited : (12)
|
|
References (0)
|